Conventional treatment approaches for malignant tumors are highly invasive and sometimes have only a palliative effect. Therefore, there is an increasing demand to develop novel, more efficient treatment options. Increased efforts have been made to apply immunomodulatory strategies in antitumor treatment. In recent years, immunizations with naked plasmid DNA encoding tumor-associated antigens have revealed a number of advantages. By DNA vaccination, antigen-specific cellular as well as humoral immune responses can be generated. The induction of specific immune responses directed against antigens expressed in tumor cells and displayed e.g., by MHC class I complexes can inhibit tumor growth and lead to tumor rejection. The improvement of vaccine efficacy has become a critical goal in the development of DNA vaccination as antitumor therapy. The use of different DNA delivery techniques and coadministration of adjuvants including cytokine genes may influence the pattern of specific immune responses induced. This brief review describes recent developments to optimize DNA vaccination against tumor-associated antigens. The prerequisite for a successful antitumor vaccination is breaking tolerance to tumor-associated antigens, which represent “self-antigens.” Currently, immunization with xenogeneic DNA to induce immune responses against self-molecules is under intensive investigation. Tumor cells can develop immune escape mechanisms by generation of antigen loss variants, therefore, it may be necessary that DNA vaccines contain more than one tumor antigen. Polyimmunization with a mixture of tumor-associated antigen genes may have a synergistic effect in tumor treatment. The identification of tumor antigens that may serve as targets for DNA immunization has proceeded rapidly. Preclinical studies in animal models are promising that DNA immunization is a potent strategy for mediating antitumor effects in vivo. Thus, DNA vaccines may offer a novel treatment for tumor patients. DNA vaccines may also be useful in the prevention of tumors with genetic predisposition. By DNA vaccination preventing infections, the development of viral-induced tumors may be avoided.
BocchiaM, BronteV, ColomboMP, VincentisAD, Di NicolaM, ForniG, LanataL, LemoliRM, MassaiaM, RondelliD, ZanonP, TuraS. Antitumor vaccination: where we stand. Haematologica85: 1172–1206, 2000.
2.
AdaGL. The immunological principles of vaccination. Lancet335: 523–526, 1990.
3.
WeinerDB, KennedyRC. Genetic vaccines. N Engl J Med341: 277–278, 1999.
4.
RobinsonHL, TorresCA. DNA vaccines. Semin Immunol9: 271–283, 1997.
5.
PardollDM, BeckerlegAM. Exposing the immunology of naked DNA vaccines. Immunity3: 165–169, 1995.
6.
DonnellyJJ, UlmerJB, ShiverJW, LiuMA. DNA vaccines. Annu Rev Immunol15: 617–648, 1997.
7.
WolffJA, MaloneRW, WilliamsP, ChongW, AcsadiG, JaniA, FeignerPL. Direct gene transfer into mouse muscle in vivo. Science247: 1465–1468, 1990.
8.
UlmerJB, DonnellyJJ, ParkerSE, RhodesGH, FeignerPL, DwarkiVJ, GromkowskiSH, DeckRR, DeWittCM, FriedmannA, HaweLA, LeanderKR, MartinezD, PerryHC, ShiverJW, MongomeryDL, LiuMA. Heterologous protection against influenza by injection of DNA encoding a viral proteinScience259: 1745–1749, 1993.
9.
WangR, DoolanDL, LeTP. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science282: 476–480, 1998.
10.
CalarotaS, BrattG, NordlundS. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet351: 1320–1325, 1998.
11.
WolffJA, LudtkeJJ, AcsadiG, WilliamsP, JaniA. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet1: 363–369, 1992.
12.
FeltquateDM. DNA vaccines: vector design, delivery, and antigen presentation. J Cell Biochem30–31(Suppl.): 304–311, 1998.
13.
TownsendA, TrowsdaleJ. The transporters associated with antigen presentation. Semin Cell Biol4: 53–61, 1993.
14.
CorrM, LeeDJ, CarsonDA, TigheH. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med184: 1555, 1996.
15.
UlmerJB, DeckRR, DewittCM, DonnellyJJ, LiuMA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen expression by non-muscle cells. Immunology89: 59, 1996.
16.
SteinmannRM. The dendritic cell system and ist role in immunogenicity. Annu Rev Immunol9: 271, 1991.
RomanM, Martin-OrozkoE, GoodmanJS. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med3: 849–854, 1997.
21.
SparwasserT, KochES, VabulasRM, HeegK, LipfordGB, EllwartJW, WagnerH. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol28: 2045–2054, 1998.
22.
IwasakiA, TorresCAT, OhashiPS, RobinsonHL, BarberBH. Both gene gun and intramuscular injection of plasmid DNA induce cytotoxic T-lymphocytes via bone-marrow derived antigen-presenting cells. J Immunol159: 11–14, 1997.
23.
FuTM, UlmerJB, CaulfieldMJ, DeckRR, FriedmannA, WangS, LiuX, DonnellyJJ, LiuMA. Priming of cytotoxic T-lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med3: 362–371, 1997.
24.
CondonC, WatkinsSC, CelluzziCM, ThompsonK, FaloLD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med2: 1122–1128, 1996.
25.
IwasakiA, CruzCSD, YoungAR, BarberBH. Epitope–specific cytotoxic T lymphocyte induction by minigene DNA immunization. Vaccine17: 2081–2088, 1999.
26.
CasaresS, InabaK, BrumaenuTD, SteinmanRM, BonaCA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med186: 1481–1486, 1997.
27.
DoeB, SelbyM, BarnettS, BaenzigerJ, WalkerCM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived dendritic cells. Proc Natl Acad Sci U S A93: 8578–8583, 1996.
28.
OssendorpF, MengedeE, CampsM, FilusR, MeliefCJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med187: 693–702, 1998.
29.
PardollDM, TopalianSL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol10: 588–594, 1998.
30.
HungK, HayashiR, Lafond-WalkerA, LowensteinC, PardollD, LevitskyH. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med188: 2357–2368, 1998.
31.
ZöllerM, ChristO. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol166: 3440–3450, 2001.
32.
NawrathM, PavlovicJ, MoellingK. Synergistic effect of a combined DNA and peptide vaccine against gp 100 in a malignant melanoma mouse model. J Mol Med79: 133–142, 2001.
33.
GuSY, HuangTM, RuanYH, MiaouH, LuCM, ChuM, MotzM, WolfH. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand84: 171, 1995.
ChenCH, WangTL, JiH, PardollDM, ChengWF, LingM, WuTC. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther8: 128–138, 2001.
37.
DankoI, WolffJA. Direct gene transfer into muscle. Vaccine12: 1499, 1994.
38.
RazER, CarsonDA, ParkerSE, PaarTB, AbaiAM, AichingerG, GromkowskiSH, SinghM, LewD, YankauckasMA, BairdSM, RhodesGH. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A91: 9519–9524, 1994.
39.
AnwerK, EarleKA, ShiM. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res16: 889–895, 1999.
40.
DeganoP, SarphieDF, BanghamCR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine16: 394–398, 1998.
41.
ChengL, ZiegelhofferPR, YangNS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci U S A90: 4455–4459, 1993.
42.
YangNS, BurkholderJ, RobertsB, MartinellB, McCabeD. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A87: 9568–9572, 1990.
43.
WilliamsRS, JohnstonSA, RiedyM, DeVitMJ, McElligottSG, SanfordJ. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci U S A88: 2726–2730, 1991.
44.
BarryMA, JohnstonSA. Biological features of genetic immunization. Vaccine15: 788, 1997.
45.
LarreginaAT, WatkinsSC, ErdosG, SpencerLA, StorkusWJ, Beer StolzD, FaloLD. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther8: 608–617, 2001.
46.
PorgadorA, IrvineKR, IwasakiA, BarberBH, RestifoNP, GermainRN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ cells after gene gun immunization. J Exp Med188: 1075–1082, 1998.
47.
AkbriO, PanjwaniN, GarciaSM, TasconR, StockingerB. DNA vaccination: transfection and activation of dendritic cells as key event for immunity. J Exp Med189: 169–178, 1999.
48.
TanigawaK, YuH, SunR, NickoloffBJ, ChangAE. Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother48: 635–643, 2000.
49.
CiernikF, BerzofskyJA, CarboneDP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing a single T cell epitope. J Immunol156: 2369–2375, 1996.
50.
DrabickJJ, Glasspool-MaloneJ, SomiariS, KingA, MaloneRW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significant enhanced by in vivo electropermeabilization. Mol Ther3: 249–255, 2001.
51.
MendirattaSK, ThailsG, EslakiNR, ThullNM, MataM, BronteV, PericleF. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res61: 859–862, 2001.
52.
DensmoreCL, OrsonFM, XuB, KinseyBM, WalrepJC, HuaP, BhogalB, KnightV. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther1: 180–188, 2000.
53.
FynanEF, WebsterRG, FullerDH, HaynesJR, SantoroJC, RobinsonHL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A90: 11478–11482, 1993.
54.
PertmerTM, RobertsTR, HaynesJr.. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol70: 6119–6125, 1996.
55.
FeltquateDM, HeaneyS, WebsterRG, RobinsonHL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol158: 2278–2284, 1997.
56.
HankeT, NeumannVC, BlanchardTJ, SweeneyP, HillAV, SmithGL, McMichaelA. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine17: 589–596, 1999.
57.
XiangZ, ErtlHC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity2: 129, 1995.
58.
KimJJ, AyyavooV, BagarazziML, ChattergoonMA, DangK, WangB, BoyerJD, WeinerDB. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol158: 816, 1997.
59.
ChenY, HuD, ElingDJ, RobbinsJ, KippsTJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res58: 1965–1971, 1998.
60.
ChowYH, HuangWL, ChiWK, ChuYD, TaoMH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol71: 169–178, 1997.
61.
ChowYH, ChiangBL, LeeYL, ChiWK, LinWC, ChenYT, TaoMH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol160: 1320–1329, 1998.
62.
SongK, ChangY, Prud'hommeGJ. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther7: 481–492, 2000.
63.
SongK, ChangY, Prud'hommeGJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic (CEA) studied in knockout mice. Gene Ther7: 1527–1535, 2000.
64.
KimJJ, YangJS, DangK, MansonKH, WeinerDB. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macquaques through the use of cytokine gene adjuvants. Clin Cancer Res7: 882s–889s, 2001.
65.
HawkinsWG, GoldJS, DyallR, WolchochJD, HoosA, BowneWB, SrinivasanR, HoughtonAN, LewisJJ. Immunization with DNA coding for gp100 results in CD4+ T cell independent antitumor immunity. Surgery128: 273–280, 2000.
66.
CharoJ, CiupituAT, Chavalier de PrevilleA, TrivediP, KleinG, HinkulaJ, KiesslingRA. Long-term memory obtained by genetic immunization results in fully protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol163: 5913–5919, 1999.
67.
GeisslerM, GesienA, TokushigeK, WandsJr.. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol158: 1231–1237, 1997.
68.
GerloniM, LoD, BallouWR, ZanettiM. Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells. Eur J Immunol28: 1832–1838, 1998.
69.
GeisslerM, SchirmbeckR, ReimannJ, BlumHE, WandsJr.. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology28: 202–210, 1998.
70.
RakhmilevichAL, ImbodenM, HaoZ, MacklinMD, RobertsT, WrightKM, AlbertiniMR, YangNS, SondelPM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and GM-CSF. Clin Cancer Res7: 952–961, 2001.
71.
XiangZ, ErtlHC. Mannipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity2: 129, 1995.
72.
KimJJ, TrivediNN, NottinghamLK, MorrisonL, TsaiA, HuY, MahalingamS, DangK, AhnL, DoyleNK. Modulation of amplitude and direction of in vivo immune responses by coadministration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol28: 1089, 1998.
73.
TaziA, BouchonnetF, GrandsaigneM, BoumsellL, HanceAJ, SolerP. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest91: 566–576, 1993.
74.
BanchereauJ, SteinmannRM. Dendritic cells and the control of immunity. Nature392: 245–252, 1998.
75.
FischerHG, FroschS, ReskeK, Reske-KunzAB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol141: 3882–3888, 1988.
76.
HungCF, HsuKF, ChengWF, ChaiCY, HeL, LingM, WuTC. Enhancement of DNA vaccine potency by linkage of antigen gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res61: 1080–1088, 2001.
77.
LeeAH, SuhYS, SungYC. DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine17: 473–479, 1999.
78.
LeeSW, ChoJH, SungYC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony stimulating factor gene. J Virol72: 8430–8436, 1998.
79.
RoveroS, BoggioK, CarloED, AmiciA, QuaglinoE, PorceddaP, MusianiP, ForniG. Insertion of the DNA for the 163-171 peptide of ILl-ß enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Gene Ther8: 447–452, 2001.
80.
LeitnerWW, YingHY, DriverDA, DubenskyTW, RestifoNP. Enhancement of tumor-specific immune response with plasmid DNA replicon vector. Cancer Res60: 51–55, 2000.
81.
DessureaultS, GrahamF, GallingerS. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 espression vector. Ann Surg Oncol3: 317–324, 1996.
82.
KoulovaL, ClarkEA, ShuG, DupontB. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med173: 759–762, 1991.
83.
CorrM, TigheH, LeeD, DudlerJ, TrieuM, BrinsonDC, CarsonD. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol159: 4999–5004, 1997.
84.
MendozaRB, CantwellMJ, KippsTJ. Immunstimulatory effects of a plasmid expression CD40 ligand (CD154) on gene immunization. J Immunol159: 5777–5781, 1997.
85.
ChenCH, WangTI, HungCF, YangY, YoungRA, PardollDM, WuTC. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res60: 1035–1042, 2000.
86.
HungCF, ChengWF, HsuKF, ChaiCY, HeL, LingM, WuTC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res61: 3698–3704, 2001.
87.
YouZ, HuangX, HesterJ, TohHC, ChenSY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res61: 3704–3711, 2001.
88.
HoughtonAN. Cancer antigens: immune recognition of self and altered self. J Exp Med180: 1–4, 1994.
89.
WeberLW, BowneWB, WolchokJD, SrinivasanR, QinJ, MoroiY, ClynesR, SongP, LewisJJ, HoughtonAN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest102: 1258–1264, 1998.
90.
OverwijkWW, TsungA, IrvineKR, ParkhurstMR, GoletzTJ, TsungK. Gp100/pmel 17 is a murine tumor rejection antigen: induction of self-reactive, tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med188: 277–286, 1998.
91.
SteitzJ, BrückJ, SteinbrinkK, EnkA, KnopJ, TütingT. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer86: 89–94, 2000.
92.
BowneWB, SrinivasanRM, WolchokDJ. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med190: 1717–1722, 1999.
93.
JagerE, RinghofferM, KarbachJ, ArandM, OeschF, KnuthA. Inverse relationship of melanocytic differentiation antigen expression in melanoma tissue and CD8+ cytotoxic T cell response: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer66: 470–476, 1996.
94.
CohenEP. Cancer therapy with DNA-based vaccines. Immunol Lett74: 59–65, 2000.
95.
SchreursMW, de BoerAJ, FigdorCG, AdemaGJ. Genetic vaccination against the melanocyte lineage–specific antigen gp100 induces cytotoxic T lymphocyte–mediated tumor protection. Cancer Res58: 2509–2514, 1998.
96.
NawrathM, PavlovicJ, DummetR, SchultzJ, StrackB. Heinrich J, Moelling K. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel 17. Leukemia13: S48–S51, 1999.
97.
WagnerSN, WagnerC, LuhrsP, WaimannTK, KutilR, GoosM, StingeG, SchneebergerA. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J Invest Dermatol115: 1082–1087, 2000.
98.
ZhaiY, YangJC, KawakamiY, SpiessP, WadsworthSC, CardozaLM, CoutureLA, SmithAE, RosenbergSA. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MARTI or gp100 for cancer therapy. J Immunol156: 700–710, 1996.
99.
ParkJH, KimCJ, LeeJH, ShinSH, ChungGH, JangYS. Effective immunotherapy of cancer by DNA vaccination. Mol Cells9: 384–391, 1999.
100.
NegliaF, OrengoAM, CilliM, MeazzaR, TomassettiA, CanevariS, MelaniC, ColomboMP, FerriniS. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor-α (Frα) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther6: 349–357, 1999.
101.
GeisslerM, WandsG, GesienA, de la MonteS, BelletD, WandsJr.. Genetic immunization with the free human chorionic gonadotropin-ß subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest76: 859–871, 1997.
102.
PupaSM, InvernizziAM, FortiS, Di CarloE, MusianiP, NanniP, LolliniPL, MeazzaR, FerriniS, MenardS. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther8: 75–79, 2001.
103.
LachmanLB, RaoXM, KremperRH, OzpolatB, KiriakovaG, PriceJE. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther8: 259–268, 2001.
104.
OhwadaA, NagaokaI, TakahashiF, TominagaS, FukuchiY. DNA vaccination against HuD antigen elicits antitumor activity in a small-cell lung cancer murine model. Am J Respir Cell Mol Biol21: 37–43, 1999.
105.
LodeHN, PertlU, XiangR, GaedickeG, ReisfeldRA. Tyrosine hydroxylase-based DNA vaccination is effective against murine neuroblastoma. Med Pediatr Oncol35: 641–646, 2000.
106.
KimJJ, TrivediNN, WilsonDM, MahalingamS, MorrisonL, TsaiA, ChattergoonMA, DangK, PatelM, AhnL, BoyerJD, ChalianAA, ShoemakerH, Kieber-EmmonsT, AgadjanyanMA, WeinerDB. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene17: 3125, 1998.
107.
StevensonFK, LinkCJ, TraynorA, YuH, CorrM. DNA vaccination against multiple myeloma. Semin Hematol36: 38–42, 1999.
108.
StevensonFK, ZhuD, KingCA, Ash worthLJ, KumarS, HawkinsRE. Idiotype DNA vaccines against B cell lymphoma. Immunol Rev145: 211, 1995.
109.
SyrengelasAT, ChenT, LevyR. DNA immunization induces protective immunity against B cell lymphoma. Nat Med2: 1038, 1996.
110.
HakimI, LevyS, LevyR. A nine-amino acid peptide from II–1ß augments antitumor immune responses induced by protein and DNA vaccines. J Immunol157: 5503, 1996.
111.
KingCA, SpellerbergMB, ZhuD, RiceJ, SahotaSS, ThompsetAR, HamblinTJ, RadlJ, StevensonFK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immuneity against lymphoma and myeloma. Nat Med4: 1281, 1998.
112.
SyrengelasAD, LevyR. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol162: 4790–4795, 1999.
113.
OhashiT, HanabuchiS, KatoH, TatenoH, TakemuraF, TsukaharaT, KoyaY, HasegawaA, MasudaT, KannagiM. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type I Tax-coding DNA vaccine. J Virol74: 9610–9616, 2000.
114.
JonsenAR, DurfySJ, BurkeW, MotulskyAG. The advent of the unpatients. Nat Med2: 622–624, 1996.
115.
LipsCJ, HoppenerJW, ThijssenJH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem38: 168–179, 2001.
116.
HauptK, SiegelF, LuM, YangD, HilkenG, MannK, RoggendorfM, SailerB. Induction of a cellular and humoral immune response against preprocalcitonin by genetic immunization: a potential new treatment for medullary thyroid carcinoma. Endocrinology142: 1017–1023, 2001.
117.
HanR, CladelNM, ReedCa, PengX, Budgeon1R, PickelM, ChristensenND. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol74: 9712–9716, 2000.
118.
HanR, ReedCA, CladelNM, ChristensenND. Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine17: 1558–1566, 1999.
119.
LipfordGB, BauerS, WagnerH, HeegK. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology84: 298–303, 1995.
120.
ChenCH, JiH, SuhKW, ChotiMA, PardollDM, WuTC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther6: 1972–1981, 1999.
121.
VeldersPV, WeijzenS, EibenGL, ElmishadAG, KloetzelPM, HigginsT, CiccarelliRB, EvansM, ManS, SmithL, KastWM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string vaccine. J Immunol166: 5366–5373, 2001.
122.
SmahelM, SimaP, LudvikovaV, VonkaV. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology281: 231–238, 2001.
